natgillin/translations-raw huggingface dataset:
Table 2: Interactions between emtricitabine/tenofovir disoproxil or its individual component(s) and other medicinal products 
Preglednica 2: Interakcije med emtricitabinom/dizoproksiltenofoviratom ali njegovo(-imi) posamično(-imi) učinkovino(-ami) in drugimi zdravili
• Emtricitabine/Tenofovir disoproxil Mylan is also used to reduce the risk of getting HIV-1 infection in adults, and adolescents aged 12 years to less than 18 years who weigh at least 35 kg, when used as a daily treatment, together with safer sex practices: 
• Zdravilo Emtricitabin/dizoproksiltenofovirat Mylan se uporablja tudi za zmanjšanje tveganja za okužbo z virusom HIV-1 pri odraslih in mladostnikih, starih od 12 do 18 let, ki tehtajo vsaj 35 kg, kadar se uporablja za vsakodnevno zdravljenje, ob hkratnem upoštevanju varnega spolnega vedenja:
• If you have hepatitis B, it is especially important not to stop your treatment with Emtricitabine/Tenofovir disoproxil Mylan without talking to your doctor first. 
• Če ste okuženi s hepatitisom B, je še zlasti pomembno, da ne prenehate z zdravljenjem z zdravilom Emtricitabin/dizoproksiltenofovirat Mylan, ne da bi se prej posvetovali z zdravnikom.
The systemic clearance of emtricitabine averaged 307 mL/min. 
Sistemski očistek emtricitabina je v povprečju 307 ml/min.
Following intravenous administration, the volume of distribution of emtricitabine and tenofovir was approximately 1.4 L/kg and 800 mL/kg, respectively. 
Po intravenskem odmerku je volumen porazdelitve emtricitabina znašal približno 1,4 l/kg in volumen porazdelitve tenofovirja približno 800 ml/kg.
Adherence Substudy Participantsb Placebo 
Sodelujoči v podštudiji adherenceb Placebo
A small clinical study was conducted to evaluate the safety, antiviral activity and pharmacokinetics of tenofovir disoproxil in combination with emtricitabine in HIV infected patients with renal impairment. 
Izvedena je bila majhna klinična študija za ocenitev varnosti, protivirusne aktivnosti in farmakokinetike dizoproksiltenofovirata v kombinaciji z emtricitabinom pri bolnikih, okuženih z virusom HIV z ledvično okvaro.
insomnia, abnormal dreams 
nespečnost, nenavadne sanje
Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours. 
Po peroralni uporabi zdravila je razpolovna doba izločanja emtricitabina približno 10 ur.
For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. 
Za nadzor lipidov in glukoze v krvi je treba upoštevati veljavne smernice za zdravljenje okužbe z virusom HIV.
Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). 
Emtricitabin se primarno izloča preko ledvic - celoten odmerek se izolira iz urina (približno 86 %) in iz blata (približno 14 %).
These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particularly neurologic findings. 
Te ugotovitve je treba upoštevati pri vseh otrocih, ki so bili in utero izpostavljeni nukleozidnim in nukleotidnim analogom, pri katerih se pojavijo resne klinične ugotovitve neznanega vzroka, še zlasti nevrološke.
Exacerbations of hepatitis after discontinuation of treatment: In HBV infected patients, clinical and laboratory evidence of hepatitis have occurred after discontinuation of treatment (see section 4.4). 
Poslabšanje hepatitisa po prekinitvi zdravljenja: Pri bolnikih, okuženih z virusom HBV, so se po prekinitvi zdravljenja pokazali klinični in laboratorijski znaki hepatitisa (glejte poglavje 4.4).
However, as would be expected in this patient population, elevations in AST and ALT occurred more frequently than in the general HIV infected population. 
Vendar je pri teh bolnikih, kot pričakovano, pogostejši porast AST in ALT, kot pri bolnikih, okuženih samo z virusom HIV.
The frequency category was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in randomised controlled clinical studies (n = 1,563) or tenofovir disoproxil in randomised controlled clinical trials and the expanded access program (n = 7,319). 
Kategorija pogostnosti je bila ocenjena s statističnim izračunom na podlagi skupnega števila bolnikov, izpostavljenih emtricitabinu v randomiziranih kontroliranih kliničnih študijah (n = 1.563) ali dizoproksiltenofoviratu v randomiziranih kontroliranih kliničnih študijah in podaljšanem programu dostopanja (n = 7.319).
• If you are an adult taking this medicine to reduce the risk of getting HIV, take this medicine every day, not just when you think you have been at risk of HIV infection. 
• Če ste odrasli in to zdravilo jemljete za zmanjšanje tveganja za okužbo s HIV, jemljite to zdravilo vsak dan, ne le takrat, ko menite, da obstaja tveganje za okužbo z virusom HIV.
Both of these active substances are antiretroviral medicines which are used to treat HIV 
Obe zdravilni učinkovini sta protiretrovirusni zdravili, ki se uporabljata za zdravljenje okužbe z virusom HIV.
However, both are generally known as NRTIs and they work by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the virus to reproduce itself. 
Oba sta splošno znana pod imenom nukleozidni zaviralci reverzne transkriptaze (NRTI, nucleoside reverse transcriptase inhibitors) in delujeta tako, da vplivata na normalno delovanje encima (reverzne transkriptaze), ki je bistven za reproduciranje virusa.
Before and during treatment, your doctor may order blood tests to measure kidney function. 
Pred in med zdravljenjem bo zdravnik morda naredil krvne preiskave, da bo preveril delovanje ledvic.
In vitro protein binding of tenofovir to plasma or serum protein was less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 μg/mL. 
In vitro je bila vezava tenofovirja na plazemske proteine manjša od 0,7 % oziroma na serumske proteine manjša od 7,2 % v koncentracijskem območju tenofovirja od 0,01 do 25 µg/ml.
Interactions between emtricitabine/tenofovir disoproxil or its individual component(s) and other medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.” and once daily as “q.d.”). 
Interakcije med emtricitabinom/dizoproksiltenofoviratom ali njegovo(-imi) posamično(-imi) učinkovino(-ami) in drugimi zdravili so navedene v preglednici 2 spodaj (povečanje je označeno z znakom ''↑'', zmanjšanje z ''↓'', brez spremembe z ''↔'', dvakrat na dan z ''b.i.d.''
• joint aches and pains (especially of the hip, knee and shoulder) 
• bolečine v sklepih (zlasti v kolku, kolenu in rami)
However, tenofovir disoproxil reduced the viability index and weight of pups in a peri and postnatal toxicity study at maternally toxic doses. 
Vendar pa je dizoproksiltenofovirat zmanjšal indeks življenjskih funkcij in težo mladičkov v peri- in postnatalni študiji toksičnosti pri odmerkih, toksičnih za mater.
• Do not share or re-use needles or other injection or drug equipment. 
• Ne delite igel ali drugih pripomočkov za injiciranje in pripomočkov za ostale oblike jemanja drog ter jih ne uporabljajte ponovno.
Additive to synergistic effects were observed in combination studies with protease inhibitors, and with nucleoside and non-nucleoside analogue inhibitors of HIV reverse transcriptase. 
Aditivne do sinergistične učinke so opazili v študijah kombinacije z zaviralci proteaz in z nukleozidnimi in nenukleozidnimi analogi zaviralcev HIV reverzne transkriptaze.
Medis International a.s vyrobani zavod Bolatice,Prumyslova, -961/16, Bolatice 747 23, Czech Republic 
Medis International a.s, vyrobani zavod Bolatice, Prumyslova, -961/16, Bolatice, 747 23, Češka
Emtricitabine/tenofovir disoproxil has not been studied in HIV-1 uninfected individuals with creatinine clearance < 60 mL/min and is therefore not recommended for use in this population. 
Emtricitabina/dizoproksiltenofovirata niso preučevali pri posameznikih, ki niso okuženi s HIV-1 in imajo očistek kreatinina < 60 ml/min, zato se ne priporoča za uporabo pri tej populaciji.
Also, emtricitabine did not inhibit uridine-5'-diphosphoglucuronyl transferase, the enzyme responsible for glucuronidation. 
Emtricitabin tudi ni inhibiral uridin-5'-difosfoglukuronil-transferaze, encima, ki je odgovoren za glukuronidacijo.
However, in some HIV-1 infected patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation. 
Vendar pa pri nekaterih bolnikih s HIV-1 upad očistka kreatinina ni povsem izzvenel kljub prekinitvi zdravljenja z dizoproksiltenofoviratom.
The mean changes in CD4 cell count from baseline were +185 cells/mm3 and +196 cells/mm3 respectively. 
Srednje spremembe števila celic CD4 so bile od začetka študije +185 celic/mm3 in +196 celic/mm3.
Oral carcinogenicity studies in rats and mice only revealed a low incidence of duodenal tumours at an extremely high dose in mice. 
Študije peroralne kancerogenosti na podganah in miših so pokazale le nizko incidenco tumorjev na dvanajstniku pri izjemno visokem odmerku pri miših.
** The p-value based on the Cochran-Mantel-Haenszel Test stratified for baseline CD4 cell count TLOVR = Time to Loss of Virologic 
** Vrednost p temelji na Cochran-Mantel-Haenszlovem testu, stratificiranem za število celic CD4 na začetku študije.
Emtricitabine triphosphate and tenofovir diphosphate competitively inhibit HIV-1 reverse transcriptase, resulting in DNA chain termination. 
Emtricitabin trifosfat in tenofovir difosfat kompetitivno inhibirata HIV-1 reverzno transkriptazo, kar rezultira v prekinitvi verige DNA.
Administration every 48 hours is recommended based on modelling of singledose pharmacokinetic data for emtricitabine and tenofovir disoproxil in non-HIV infected subjects with varying degrees of renal impairment (see section 4.4). 
Priporočljiv je odmerek vsakih 48 ur, kar temelji na podatkih o farmakokinetiki enkratnih odmerkov za emtricitabin in dizoproksiltenofovirat pri osebah, ki niso okužene s HIV, z različnimi stopnjami ledvične okvare (glejte poglavje 4.4).
b Substudy participants received active adherence monitoring, e.g. unannounced home visits and pill counts, and counselling to improve compliance with study drug. 
b Sodelujoče v podštudiji so spremljali glede aktivne adherence, npr. nenajavljeni domači obiski in štetje tablet.
Discontinuation of emtricitabine/tenofovir disoproxil therapy in patients infected with HBV may be associated with severe acute exacerbations of hepatitis. 
Prekinitev zdravljenja z emtricitabinom/dizoproksiltenofoviratom pri bolnikih z okužbo s HBV je lahko povezana s hudimi akutnimi poslabšanji hepatitisa.
Possible serious side effects: 
Možni resni neželeni učinki:
URAI = unprotected receptive anal intercourse 
URAI = nezaščiten receptivni analni spolni odnos
There is close structural similarity between lamivudine and emtricitabine and similarities in the pharmacokinetics and pharmacodynamics of these two agents. 
Med lamivudinom in emtricitabinom obstaja velika strukturna podobnost in tudi podobnosti v farmakokinetiki in farmakodinamiki teh dveh zdravil.
Emtricitabine-resistant viruses with the M184V/I mutation were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir and zidovudine. 
Virusi odporni na emtricitabin z mutacijo M184V/I so bili navzkrižno odporni na lamivudin, a so ohranili občutljivost za didanozin, stavudin, tenofovir in zidovudin.
Adherence Substudy 
Podštudija adherence
Therefore, the same problems may be seen if emtricitabine/tenofovir disoproxil is administered with a third nucleoside analogue. 
Zato je možno opaziti enake težave pri jemanju emtricitabina/dizoproksiltenofovirata s tretjim analogom nukleozidov.
Administration of emtricitabine/tenofovir disoproxil with food resulted in a delay of approximately three quarters of an hour in reaching maximum tenofovir concentrations and increases in tenofovir AUC and Cmax of approximately 35% and 15%, respectively, when administered with a high fat or light meal, compared to administration in the fasted state. 
Jemanje emtricitabina/dizoproksiltenofovirata s hrano se je odražalo v približno tričetrturni zakasnitvi pri doseganju maksimalne koncentracije tenofovirja ter povečanju AUC tenofovirja za približno 35 % in Cmax za približno 15 % pri jemanju ob z maščobami bogatem ali lažjem obroku, v primerjavi z jemanjem na tešče.
• problems with digestion resulting in discomfort after meals, feeling bloated, flatulence 
• prebavne motnje, ki privedejo do slabega počutja po zaužitem obroku, občutek napihnjenosti,
Excipient with known effect 
Pomožna snov z znanim učinkom
If clinical symptoms consistent with acute viral infection are present and recent (< 1 month) exposures to HIV-1 are suspected, use of emtricitabine/tenofovir disoproxil should be delayed for at least one month and HIV-1 status reconfirmed before starting emtricitabine/tenofovir disoproxil for pre-exposure prophylaxis. 
Če so prisotni klinični simptomi akutne virusne okužbe in obstaja sum na nedavno (< 1 mesec) izpostavljenost virusu HIV-1, je treba jemanje emtricitabina/dizoproksiltenofovirata zamakniti za najmanj en mesec in ponovno potrditi status okužbe s HIV-1 pred začetkom jemanja emtricitabina/dizoproksiltenofovirata za zaščito pred izpostavljenostjo.
8% (-1% to 17%) 
8 % (-1 % do 17 %)
In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP450 mediated interactions involving emtricitabine and tenofovir disoproxil with other medicinal products is low. 
In vitro in klinične študije farmakokinetičnih interakcij so pokazale, da je možnost za s CYP450 posredovane interakcije emtricitabina in dizoproksiltenofovirata z drugimi zdravili majhna.
The following may be signs of lactic acidosis: 
Naslednji znaki lahko kažejo na laktacidozo:
Co-administration and risk of renal toxicity 
Sočasna uporaba in tveganje toksičnosti za ledvice
• If you are being treated for HIV infection your doctor will prescribe Emtricitabine/Tenofovir disoproxil Mylan with other antiretroviral medicines. 
• Če se zdravite zaradi okužbe s HIV, vam bo zdravnik predpisal zdravilo Emtricitabin/dizoproksiltenofovirat Mylan skupaj z drugimi protiretrovirusnimi zdravili.
Mylan Hungary Kft Mylan utca 1, H-2900 Komárom, Hungary 
Izdelovalci Mylan Hungary Kft, Mylan utca 1, H-2900 Komárom, Madžarska
When using emtricitabine/tenofovir disoproxil for pre-exposure prophylaxis individuals should be reassessed at each visit to ascertain whether they remain at high risk of HIV-1 infection. 
Pri uporabi emtricitabina/dizoproksiltenofovirata pri posameznikih za zaščito pred izpostavitvijo je treba ob vsakem obisku ponovno oceniti, ali so še vedno močno izpostavljeni tveganju za okužbo z virusom HIV-1.
The use of emtricitabine/tenofovir disoproxil is not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min) and in patients who require haemodialysis since appropriate dose reductions cannot be achieved with the combination tablet (see sections 4.2 and 5.2). 
Uporaba emtricitabina/dizoproksiltenofovirata se ne priporoča pri bolnikih s hudo ledvično okvaro (očistek kreatinina < 30 ml/min) in bolnikih, ki potrebujejo hemodializo, ker ustreznega zmanjšanja odmerka ni mogoče doseči s kombinirano tableto (glejte poglavji 4.2 in 5.2).
In addition, the clinical response to treatment should be closely monitored in patients receiving emtricitabine/tenofovir disoproxil at a prolonged dosing interval. 
Poleg tega je treba skrbno spremljati klinični odziv na zdravljenje pri bolnikih, ki prejemajo emtricitabin/dizoproksiltenofovirat s podaljšanim intervalom med odmerki.
• That Emtricitabine/Tenofovir disoproxil Mylan may cause a reduction in BMD and the effects of Emtricitabine/Tenofovir disoproxil Mylan associated changes in BMD on long term bone health and future fracture risk are currently unknown in paediatric patients 
• da lahko zdravilo Emtricitabin/dizoproksiltenofovirat Mylan vpliva na zmanjšanje MKG in da spremembe MKG zaradi učinkov zdravila Emtricitabin/dizoproksiltenofovirat Mylan na dolgoročno zdravje kosti in prihodnje tveganje zlomov pri pediatričnih bolnikih trenutno niso znani;
Repeated dose toxicity studies in rats, dogs and monkeys at exposure levels greater than or equal to clinical exposure levels and with possible relevance to clinical use include renal and bone toxicity and a decrease in serum phosphate concentration. 
Ugotovitve iz študij toksičnosti pri ponavljajočih odmerkih pri podganah, psih in opicah pri stopnjah izpostavljenosti, ki so bile večje ali enake stopnjam klinične izpostavljenosti, in ki so morda pomembne za klinično uporabo, vključujejo toksičen vpliv na ledvice in kosti in zmanjšanje koncentracije serumskega fosfata.
increased creatinine, proteinuria, proximal renal tubulopathy including Fanconi syndrome 
povišan kreatinin, proteinurija, proksimalna ledvična tubulopatija, vključujoč Fanconijev sindrom
HIV-1 expressing three or more thymidine analogue associated mutations (TAMs) that included either the M41L or L210W reverse transcriptase mutation showed reduced susceptibility to tenofovir disoproxil. 
HIV-1, ki je izražal tri ali več mutacij povezanih z analogom timidina (TAM, thymidine-analogue associated mutations), ki so vključevale ali M41L ali L210W mutacijo reverzne transkriptaze, je pokazal zmanjšano občutljivost za zdravljenje z dizoproksiltenofoviratom.
Difference (95%CI) 
Razlika (95-odstotni IZ)
The risk of HIV-1 infection should be balanced against the potential for renal and bone effects with long-term use of emtricitabine/tenofovir disoproxil. 
Tveganje za okužbo z virusom HIV-1 je treba presoditi glede na možne učinke na ledvice in kosti pri dolgotrajni uporabi emtricitabina/dizoproksiltenofovirata.
At week 48, six adolescents in the tenofovir disoproxil group and one adolescent in the placebo group had significant lumbar spine BMD loss (defined as > 4% loss). 
V 48. tednu so imeli šest mladostnikov v skupini z dizoproksiltenofoviratom in en mladostnik v skupini s placebom pomembno zmanjšanje MGK ledvene hrbtenice (opredeljeno kot zmanjšanje > 4 %).
The marketing authorisation holder (MAH) shall ensure that all physicians who are expected to prescribe/use Emtricitabine/Tenofovir disoproxil Mylan in either adolescent patients for the treatment of HIV-1 infection or in adults and adolescents for PrEP are provided with a physician educational pack containing the Summary of Product Characteristics and an appropriate educational brochure, as detailed below: 
Imetnik dovoljenja za promet z zdravilom zagotovi, da vsi zdravniki, ki naj bi predpisovali/uporabljali zdravilo Emtricitabin/dizoproksiltenofovirat Mylan za zdravljenje mladostnikov, okuženih z virusom HIV-1, ali za PrEP pri odraslih in mladostnikih, prejmejo izobraževalni paket za zdravnike, ki vsebuje Povzetek glavnih značilnosti zdravila in ustrezno izobraževalno gradivo, kot je navedeno v nadaljevanju:
Efficacy was strongly correlated with adherence as assessed by detection of plasma or intracellular drug levels in a case-control study (Table 7). 
Učinkovitost je bila močno odvisna od adherence, kar je bilo ocenjeno z zaznavanjem koncentracij učinkovine v plazmi ali znotraj celic v kontrolni študiji (preglednica 7).
If you accidentally take more than the recommended dose of Emtricitabine/Tenofovir disoproxil Mylan, contact your doctor or nearest emergency department for advice. 
Če ste pomotoma zaužili odmerek zdravila Emtricitabin/dizoproksiltenofovirat Mylan, večji od priporočenega, se posvetujte z zdravnikom ali poiščite najbližjo urgentno ambulanto.
Separate preparations of emtricitabine and tenofovir disoproxil are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of 
Posamezni pripravki emtricitabina in dizoproksiltenofovirata so na voljo za zdravljenje okužbe z virusom HIV-1, če je treba prekiniti terapijo ali prilagoditi odmerek ene od učinkovin zdravila
At baseline the randomised groups had similar median plasma HIV-1 RNA (5.02 and 5.00 log10 copies/mL) and CD4 counts (233 and 241 cells/mm3). 
Na začetku študije so imele randomizirane skupine podobno mediano števila HIV-1 RNA v plazmi (5,02 in 5,00 log10 kopij/ml) in CD4 (233 in 241 celic/mm3).
If you have difficulty swallowing, you can use the tip of a spoon to crush the tablet. 
• Če imate težave s požiranjem, lahko tableto zdrobite s konico žlice.
Elderly: No dose adjustment is required (see section 5.2). 
Starostniki: Prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
• Genotypic resistance to efavirenz, predominantly the K103N mutation, developed in virus from 13/19 (68%) patients in the emtricitabine/tenofovir disoproxil/efavirenz group and in virus from 21/29 (72%) patients in the comparative group. 
• genotipska rezistenca za efavirenz, predvsem mutacija K103N, se je razvila v virus pri 13/19 (68 %) bolnikov v skupini, ki je prejemala emtricitabin/dizoproksiltenofovirat/efavirenz, in pri 21/29 (72 %) bolnikov v primerjalni skupini.
Individuals over the age of 65 years are more likely to have decreased renal function, therefore caution should be exercised when administering emtricitabine/tenofovir disoproxil to older people. 
Obstaja večja verjetnost, da je ledvična funkcija pri posameznikih, starejših od 65 let, zmanjšana, zato je pri dajanju emtricitabina/dizoproksiltenofovirata starejšim ljudem potrebna previdnost.
Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). 
Redko so poročali o nekaterih primerih nevroloških motenj, ki nastopijo kasneje (hipertonija, konvulzije, nenormalno obnašanje).
• difficulty with movement  If you notice any of these symptoms tell your doctor. 
• omejena gibljivost  Če opazite katerega od teh simptomov, obvestite zdravnika.
Weight and metabolic parameters 
Telesna masa in presnovni parametri
• Know your hepatitis B virus (HBV) infection status before starting Emtricitabine/Tenofovir disoproxil Mylan. 
• Ugotovite stanje okužbe z virusom hepatitisa B (HBV) pred začetkom jemanja zdravila Emtricitabin/dizoproksiltenofovirat Mylan.
Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. 
Nukleozidni in nukleotidni analogi lahko v različnih stopnjah vplivajo na mitohondrijsko funkcijo, kar je najbolj izrazito pri stavudinu, didanozinu in zidovudinu.
Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (aged 12 to < 18 years) with body weight ≥ 35 kg and in 23 HIV-1 infected children aged 2 to < 12 years. 
Farmakokinetične lastnosti tenofovirja v stanju dinamičnega ravnovesja so bile ocenjene pri 8 mladostnikih s HIV-1 (starih od 12 do < 18 let) s telesno maso ≥ 35 kg in pri 23 otrocih s HIV-1, starih od 2 do < 12 let.
 If you notice any of the side effects listed above or if any of the side effects get serious, talk to your doctor or pharmacist. 
 Če opazite katerega od zgoraj navedenih neželenih učinkov ali če kateri koli od neželenih učinkov postane resen, se posvetujte z zdravnikom ali farmacevtom.
Rare: 
Redko:
• Adolescents aged 12 to less than 18 years who weigh at least 35 kg: one tablet each day, whenever possible with food. 
• Mladostniki, stari od 12 do 18 let, ki tehtajo vsaj 35 kg: ena tableta vsak dan s hrano, če je mogoče.
Emtricitabine and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion. 
Emtricitabin in tenofovir se primarno izločata preko ledvic s kombinacijo glomerularne filtracije in aktivne tubulne sekrecije.
• Always practice safer sex. Use condoms to reduce contact with semen, vaginal fluids, or blood. 
Uporabljajte kondome, da zmanjšate stik s semensko tekočino, vaginalnimi izločki ali krvjo.